Interestingly, in the subgroup analysis, positive PD-L1 immunostaining in tumor cells was associated with better PFS in patients not carrying activation of DNA damage repair components, as defined by the presence of ARID1A mutations and negative pATM expression. Here, ARID1A is linked to neoplasm.